Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Comparative oncology approach to drug repurposing in osteosarcoma.

Parrales A, McDonald P, Ottomeyer M, Roy A, Shoenen FJ, Broward M, Bruns T, Thamm DH, Weir SJ, Neville KA, Iwakuma T, Fulbright JM.

PLoS One. 2018 Mar 26;13(3):e0194224. doi: 10.1371/journal.pone.0194224. eCollection 2018.

2.

Cooperative p16 and p21 action protects female astrocytes from transformation.

Kfoury N, Sun T, Yu K, Rockwell N, Tinkum KL, Qi Z, Warrington NM, McDonald P, Roy A, Weir SJ, Mohila CA, Deneen B, Rubin JB.

Acta Neuropathol Commun. 2018 Feb 20;6(1):12. doi: 10.1186/s40478-018-0513-5.

3.

Pharmacokinetics of two 6-mercaptopurine liquid formulations in children with acute lymphoblastic leukemia.

Tolbert JA, Bai S, Abdel-Rahman SM, August KJ, Weir SJ, Kearns GL, Neville KA.

Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26465. Epub 2017 Mar 10.

PMID:
28295989
4.

In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma.

Pessetto ZY, Chen B, Alturkmani H, Hyter S, Flynn CA, Baltezor M, Ma Y, Rosenthal HG, Neville KA, Weir SJ, Butte AJ, Godwin AK.

Oncotarget. 2017 Jan 17;8(3):4079-4095. doi: 10.18632/oncotarget.13385.

5.

DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway.

Parrales A, Ranjan A, Iyer SV, Padhye S, Weir SJ, Roy A, Iwakuma T.

Nat Cell Biol. 2016 Nov;18(11):1233-1243. doi: 10.1038/ncb3427. Epub 2016 Oct 24.

6.

Impact of HuR inhibition by the small molecule MS-444 on colorectal cancer cell tumorigenesis.

Blanco FF, Preet R, Aguado A, Vishwakarma V, Stevens LE, Vyas A, Padhye S, Xu L, Weir SJ, Anant S, Meisner-Kober N, Brody JR, Dixon DA.

Oncotarget. 2016 Nov 8;7(45):74043-74058. doi: 10.18632/oncotarget.12189.

7.

Quinomycin A targets Notch signaling pathway in pancreatic cancer stem cells.

Ponnurangam S, Dandawate PR, Dhar A, Tawfik OW, Parab RR, Mishra PD, Ranadive P, Sharma R, Mahajan G, Umar S, Weir SJ, Sugumar A, Jensen RA, Padhye SB, Balakrishnan A, Anant S, Subramaniam D.

Oncotarget. 2016 Jan 19;7(3):3217-32. doi: 10.18632/oncotarget.6560.

8.

RNA binding protein RBM3 increases ╬▓-catenin signaling to increase stem cell characteristics in colorectal cancer cells.

Venugopal A, Subramaniam D, Balmaceda J, Roy B, Dixon DA, Umar S, Weir SJ, Anant S.

Mol Carcinog. 2016 Nov;55(11):1503-1516. doi: 10.1002/mc.22404. Epub 2015 Aug 31.

9.

A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies.

Williamson SK, Johnson GA, Maulhardt HA, Moore KM, McMeekin DS, Schulz TK, Reed GA, Roby KF, Mackay CB, Smith HJ, Weir SJ, Wick JA, Markman M, diZerega GS, Baltezor MJ, Espinosa J, Decedue CJ.

Cancer Chemother Pharmacol. 2015 May;75(5):1075-87. doi: 10.1007/s00280-015-2737-4. Epub 2015 Apr 23.

10.

Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for gastrointestinal stromal tumor.

Pessetto ZY, Ma Y, Hirst JJ, von Mehren M, Weir SJ, Godwin AK.

Mol Cancer Ther. 2014 Oct;13(10):2276-87. doi: 10.1158/1535-7163.MCT-14-0043. Epub 2014 Aug 13.

11.

A mortality event in wrasse species (Labridae) associated with the presence of viral haemorrhagic septicaemia virus.

Munro ES, McIntosh RE, Weir SJ, Noguera PA, Sandilands JM, Matejusova I, Mayes AS, Smith R.

J Fish Dis. 2015 Apr;38(4):335-41. doi: 10.1111/jfd.12237. Epub 2014 Mar 24.

PMID:
24661037
12.

Multilocus variable-number tandem-repeat genotyping of Renibacterium salmoninarum, a bacterium causing bacterial kidney disease in salmonid fish.

Matejusova I, Bain N, Colquhoun DJ, Feil EJ, McCarthy U, McLennan D, Snow M, Verner-Jeffreys D, Wallace IS, Weir SJ, Hall M.

BMC Microbiol. 2013 Dec 6;13:285. doi: 10.1186/1471-2180-13-285.

13.

Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies.

Minden MD, Hogge DE, Weir SJ, Kasper J, Webster DA, Patton L, Jitkova Y, Hurren R, Gronda M, Goard CA, Rajewski LG, Haslam JL, Heppert KE, Schorno K, Chang H, Brandwein JM, Gupta V, Schuh AC, Trudel S, Yee KW, Reed GA, Schimmer AD.

Am J Hematol. 2014 Apr;89(4):363-8. doi: 10.1002/ajh.23640. Epub 2014 Mar 3.

14.

Drug repurposing for gastrointestinal stromal tumor.

Pessetto ZY, Weir SJ, Sethi G, Broward MA, Godwin AK.

Mol Cancer Ther. 2013 Jul;12(7):1299-309. doi: 10.1158/1535-7163.MCT-12-0968. Epub 2013 May 8.

15.

A novel, unusually efficacious duocarmycin carbamate prodrug that releases no residual byproduct.

Wolfe AL, Duncan KK, Parelkar NK, Weir SJ, Vielhauer GA, Boger DL.

J Med Chem. 2012 Jun 28;55(12):5878-86. doi: 10.1021/jm300330b. Epub 2012 Jun 12.

16.

CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.

Subramaniam D, Periyasamy G, Ponnurangam S, Chakrabarti D, Sugumar A, Padigaru M, Weir SJ, Balakrishnan A, Sharma S, Anant S.

Mol Cancer Ther. 2012 Jul;11(7):1598-608. doi: 10.1158/1535-7163.MCT-12-0102. Epub 2012 Apr 24.

17.

Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public-private partnership.

Weir SJ, DeGennaro LJ, Austin CP.

Cancer Res. 2012 Mar 1;72(5):1055-8. doi: 10.1158/0008-5472.CAN-11-3439. Epub 2012 Jan 13. No abstract available.

18.

Wnt inhibitor screen reveals iron dependence of ╬▓-catenin signaling in cancers.

Song S, Christova T, Perusini S, Alizadeh S, Bao RY, Miller BW, Hurren R, Jitkova Y, Gronda M, Isaac M, Joseph B, Subramaniam R, Aman A, Chau A, Hogge DE, Weir SJ, Kasper J, Schimmer AD, Al-awar R, Wrana JL, Attisano L.

Cancer Res. 2011 Dec 15;71(24):7628-39. doi: 10.1158/0008-5472.CAN-11-2745. Epub 2011 Oct 18.

19.

The repositioning of the anti-fungal agent ciclopirox olamine as a novel therapeutic agent for the treatment of haematologic malignancy.

Weir SJ, Patton L, Castle K, Rajewski L, Kasper J, Schimmer AD.

J Clin Pharm Ther. 2011 Apr;36(2):128-34. doi: 10.1111/j.1365-2710.2010.01172.x. Epub 2010 Aug 24.

PMID:
21366640
20.

Design, synthesis, and evaluation of duocarmycin O-amino phenol prodrugs subject to tunable reductive activation.

Lajiness JP, Robertson WM, Dunwiddie I, Broward MA, Vielhauer GA, Weir SJ, Boger DL.

J Med Chem. 2010 Nov 11;53(21):7731-8. doi: 10.1021/jm1010397.

21.

A unique class of duocarmycin and CC-1065 analogues subject to reductive activation.

Jin W, Trzupek JD, Rayl TJ, Broward MA, Vielhauer GA, Weir SJ, Hwang I, Boger DL.

J Am Chem Soc. 2007 Dec 12;129(49):15391-7. Epub 2007 Nov 17.

22.
23.

Single and multiple dose pharmacokinetics of rifapentine in man: part II.

Keung A, Eller MG, McKenzie KA, Weir SJ.

Int J Tuberc Lung Dis. 1999 May;3(5):437-44.

PMID:
10331734
24.
25.

Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study.

Keung AC, Owens RC Jr, Eller MG, Weir SJ, Nicolau DP, Nightingale CH.

Antimicrob Agents Chemother. 1999 May;43(5):1230-3.

26.
27.

Single- and multiple-dose pharmacokinetics of oral dolasetron and its active metabolites in healthy volunteers: part 2.

Dimmitt DC, Choo YS, Martin LA, Arumugham T, Hahne WF, Weir SJ.

Biopharm Drug Dispos. 1999 Jan;20(1):41-8.

PMID:
10086836
28.

Intravenous pharmacokinetics and absolute oral bioavailability of dolasetron in healthy volunteers: part 1.

Dimmitt DC, Choo YS, Martin LA, Arumugham T, Hahne WF, Weir SJ.

Biopharm Drug Dispos. 1999 Jan;20(1):29-39.

PMID:
10086835
29.

Pharmacokinetics of dolasetron with coadministration of cimetidine or rifampin in healthy subjects.

Dimmitt DC, Cramer MB, Keung A, Arumugham T, Weir SJ.

Cancer Chemother Pharmacol. 1999;43(2):126-32.

PMID:
9923817
30.
31.

Single-dose pharmacokinetics of rifapentine in women.

Keung AC, Eller MG, Weir SJ.

J Pharmacokinet Biopharm. 1998 Feb;26(1):75-85.

PMID:
9773393
32.

Pharmacokinetics of oral and intravenous dolasetron mesylate in patients with renal impairment.

Dimmitt DC, Shah AK, Arumugham T, Cramer MB, Halstenson C, Horton M, Weir SJ.

J Clin Pharmacol. 1998 Sep;38(9):798-806.

PMID:
9753207
33.

Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination.

Weir SJ, Dimmitt DC, Lanman RC, Morrill MB, Geising DH.

Biopharm Drug Dispos. 1998 Sep;19(6):365-71.

PMID:
9737817
34.

Single-dose pharmacokinetics of rifapentine in elderly men.

Keung AC, Eller MG, Weir SJ.

Pharm Res. 1998 Aug;15(8):1286-91.

PMID:
9706063
35.

Disposition and metabolism of 14C-rifapentine in healthy volunteers.

Reith K, Keung A, Toren PC, Cheng L, Eller MG, Weir SJ.

Drug Metab Dispos. 1998 Aug;26(8):732-8.

36.

Pharmacokinetics of rifapentine in patients with varying degrees of hepatic dysfunction.

Keung AC, Eller MG, Weir SJ.

J Clin Pharmacol. 1998 Jun;38(6):517-24.

PMID:
9650541
37.

Selection of doses for phase II clinical trials based on pharmacokinetic variability consideration.

Yu DK, Bhargava VO, Weir SJ.

J Clin Pharmacol. 1997 Aug;37(8):673-8.

PMID:
9378839
38.

Pharmacokinetics of MDL 26479, a novel benzodiazepine inverse agonist, in normal volunteers.

Robbins DK, Hutcheson SJ, Miller TD, Green VI, Bhargava VO, Weir SJ.

Biopharm Drug Dispos. 1997 May;18(4):325-34.

PMID:
9158880
39.

An investigation of the dose proportionality of deflazacort pharmacokinetics.

Rao N, Bhargava VO, Reynolds DL, Eller MG, Weir SJ.

Biopharm Drug Dispos. 1996 Dec;17(9):753-60.

PMID:
8968528
40.

The relative bioavailability of two marketed controlled release diltiazem dosage forms at steady state in healthy volunteers.

Lippert CL, Arumugham T, Bhargava VO, Eller M, Weir SJ.

Biopharm Drug Dispos. 1996 Jan;17(1):43-53.

PMID:
8991490
41.

Percutaneous absorption of ketoprofen from different anatomical sites in man.

Shah AK, Wei G, Lanman RC, Bhargava VO, Weir SJ.

Pharm Res. 1996 Jan;13(1):168-72.

PMID:
8668669
42.

Population pharmacokinetics of teicoplanin in patients with endocarditis.

Yu DK, Nordbrock E, Hutcheson SJ, Lewis EW, Sullivan W, Bhargava VO, Weir SJ.

J Pharmacokinet Biopharm. 1995 Feb;23(1):25-39.

PMID:
8576842
43.

Pharmacokinetics of 5-aminosalicylic acid from controlled-release capsules in man.

Yu DK, Morrill B, Eichmeier LS, Lanman RC, Lanman MB, Giesing DH, Weir SJ.

Eur J Clin Pharmacol. 1995;48(3-4):273-7.

PMID:
7589054
44.

A comparison of population and standard two-stage pharmacokinetic analyses of vigabatrin data.

Yu DK, Hutcheson SJ, Wei G, Bhargava VO, Weir SJ.

Biopharm Drug Dispos. 1994 Aug;15(6):473-84.

PMID:
7993985
45.

Single and multiple oral dose pharmacokinetics of clentiazem in normal volunteers.

Bhargava VO, Shah AK, Weir SJ, Nordbrock EE, Giesing DH.

J Clin Pharmacol. 1993 May;33(5):439-43.

PMID:
8331200
46.

Pharmacokinetics of clentiazem after intravenous and oral administration in healthy subjects.

Shah AK, Bhargava VO, Weir SJ, Giesing DH.

J Clin Pharmacol. 1993 Apr;33(4):354-9.

PMID:
8473551
47.
48.
49.

Amiodarone pharmacokinetics. II. Disposition kinetics following subchronic administration in rats.

Weir SJ, Ueda CT.

Biopharm Drug Dispos. 1987 Sep-Oct;8(5):449-60.

PMID:
3663881
50.

Amiodarone pharmacokinetics. I. Acute dose-dependent disposition studies in rats.

Weir SJ, Ueda CT.

J Pharmacokinet Biopharm. 1986 Dec;14(6):601-13.

PMID:
3820092

Supplemental Content

Support Center